X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (65) 65
humans (58) 58
hematology (43) 43
oncology (41) 41
male (39) 39
middle aged (39) 39
female (37) 37
aged (32) 32
adult (26) 26
rituximab (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
ibrutinib (22) 22
leukemia, lymphocytic, chronic, b-cell - drug therapy (21) 21
treatment outcome (20) 20
leukemia (18) 18
therapy (18) 18
aged, 80 and over (16) 16
cll (16) 16
chronic lymphocytic leukemia (15) 15
disease-free survival (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
lymphoma (14) 14
chronic lymphocytic-leukemia (13) 13
lymphomas (13) 13
prognosis (13) 13
transplantation (13) 13
cancer (12) 12
chemotherapy (12) 12
cyclophosphamide (12) 12
fludarabine (12) 12
open-label (12) 12
analysis (11) 11
leukemia, lymphocytic, chronic, b-cell - mortality (11) 11
abridged index medicus (10) 10
care and treatment (10) 10
chronic lymphatic leukemia (10) 10
clinical trials (10) 10
retrospective studies (10) 10
survival (10) 10
b-cell lymphoma (9) 9
pyrazoles - adverse effects (9) 9
pyrimidines - adverse effects (9) 9
survival rate (9) 9
antineoplastic agents - therapeutic use (8) 8
leukemia, lymphocytic, chronic, b-cell - pathology (8) 8
patient outcomes (8) 8
recurrence (8) 8
remission induction (8) 8
article (7) 7
idelalisib (7) 7
leukemia, lymphocytic, chronic, b-cell - genetics (7) 7
mutations (7) 7
non-hodgkin lymphoma (7) 7
non-hodgkins-lymphoma (7) 7
patients (7) 7
antineoplastic agents - adverse effects (6) 6
chronic lymphocytic leukaemia (6) 6
cohort studies (6) 6
hematology, oncology and palliative medicine (6) 6
medical prognosis (6) 6
medical research (6) 6
multicenter (6) 6
progression-free survival (6) 6
pyrazoles - administration & dosage (6) 6
pyrimidines - administration & dosage (6) 6
risk factors (6) 6
survival analysis (6) 6
venetoclax (6) 6
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
chromosome deletion (5) 5
diagnosis (5) 5
diffuse large b-cell lymphoma (5) 5
disease progression (5) 5
drug therapy (5) 5
expression (5) 5
follow-up (5) 5
hemic and lymphatic diseases (5) 5
immunochemotherapy (5) 5
immunotherapy (5) 5
lymphoma, large b-cell, diffuse - drug therapy (5) 5
lymphoma, large b-cell, diffuse - mortality (5) 5
mutation (5) 5
myc (5) 5
outcomes (5) 5
proteins (5) 5
relapse (5) 5
thalidomide - administration & dosage (5) 5
thalidomide - analogs & derivatives (5) 5
toxicity (5) 5
trial (5) 5
acute myeloid leukemia (4) 4
antibodies, monoclonal, murine-derived - adverse effects (4) 4
antineoplastic agents - administration & dosage (4) 4
b-cell (4) 4
bortezomib (4) 4
calcium (4) 4
chemoimmunotherapy (4) 4
combination (4) 4
cyclophosphamide - adverse effects (4) 4
disease management (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4758 - 4758
Abstract BACKGROUND Most CLL patients in the US are treated with chemoimmunotherapy (CIT) or ibrutinib; rarely do patients receive chemotherapy (CT) alone. VEN... 
Journal Article
CANCER JOURNAL, ISSN 1528-9117, 11/2019, Volume 25, Issue 6, pp. 442 - 448
The landscape of chronic lymphocytic leukemia has transformed in the era of small molecule inhibitor targeted therapies. While randomized controlled trials... 
ibrutinib | survival outcome | MULTICENTER | chronic lymphocytic leukemia | real-world evidence | Adverse events | ONCOLOGY | RITUXIMAB | OPEN-LABEL | idelalisib | OUTCOMES | venetoclax
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 16, pp. 1592 - 1593
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 5 - 6
Journal Article
PET Clinics, ISSN 1556-8598, 07/2019, Volume 14, Issue 3, pp. 405 - 410
Chronic lymphocytic leukemia (CLL)is the most common leukemia in the United States. In 1-10% of cases, it can undergo Richter's transformation (RT)to either... 
Accelerated CLL | B-cell receptor inhibitor | Chronic lymphocytic leukemia | Richter transformation | PET/CT | Ibrutinib | Venetoclax | Leukemia, Lymphocytic, Chronic, B-Cell - diagnostic imaging | Biopsy | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Positron Emission Tomography Computed Tomography - methods
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5556 - 5556
Abstract Introduction While the initial approval of venetoclax (VEN), a BCL2 inhibitor, was limited to relapsed patients with del17p, the data from the phase 3... 
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2017, Volume 377, Issue 26, pp. 2545 - 2554
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 65 - 75
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1706 - 1706
Abstract Introduction: Venetoclax (VEN) is a highly effective agent for chronic lymphocytic leukemia (CLL) that targets BCL-2. Thus, it has been hypothesized... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4299 - 4299
BACKGROUND: Recent prospective randomized phase III studies that include targeted agents in first-line (1L) chronic lymphocytic leukemia (CLL) all demonstrate... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2017, Volume 35, Issue 16, pp. 1863 - 1864
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4845 - 4845
Abstract Introduction Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma associated with a poor prognosis. The approval of ibrutinib in... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4757 - 4757
Abstract INTRODUCTION: CLL pts requiring first-line therapy are usually treated with either ibrutinib, chemotherapy alone including monoclonal antibodies (CT),... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2306 - 2306
Abstract Introduction: Novel targeted therapies greatly improved outcomes of patients with chronic lymphocytic leukemia (CLL). Among these, ibrutinib is the... 
Journal Article
The New England journal of medicine, 04/2016, Volume 374, Issue 16, pp. 1592 - 1593
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.